Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease Clear all
Completed Phase 4 Interventional Results available

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

NCT01966107
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
Interventions
Aclidinium Bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
3,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
433
States / cities
Birmingham, Alabama • Florence, Alabama • Foley, Alabama + 334 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Jun 7, 2026, 9:22 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
66
States / cities
Foley, Alabama • Mobile, Alabama • Sheffield, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

NCT02296138
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
olodaterol, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
7,903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
117
States / cities
Andalusia, Alabama • Birmingham, Alabama • Florence, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

NCT02138916
View directory record Official record
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
138
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

NCT02343458
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
44
States / cities
Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01085045
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT003 MDI, PT005 MDI, Placebo MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®), Formoterol Fumarate 12 μg (Foradil® Aerolizer®), PT001 MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Clearwater, Florida • Charlotte, North Carolina • Medford, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

NCT02727660
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disorder
Interventions
BFF MDI (PT009) 320/9.6 μg, BFF MDI (PT009) 160/9.6 μg, FF MDI (PT005) 9.6 μg
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
121
States / cities
Dothan, Alabama • Huntsville, Alabama • Sheffield, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

NCT04053634
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
84
States / cities
Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

NCT02155660
View directory record Official record
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
2,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
151
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Montgomery, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT02536508
View directory record Official record
Conditions
COPD
Interventions
BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BFF MDI 320/9.6 μg
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
64
States / cities
Dothan, Alabama • Jasper, Alabama • Peoria, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD

NCT02454959
View directory record Official record
Conditions
COPD
Interventions
GFF MDI (PT003) with Aerochamber, GFF MDI (PT003) without Aerochamber
Device
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

NCT02766608
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disorder
Interventions
BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg, BD MDI 320 μg, Symbicort® TBH 400/12 μg BID
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
2,389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
83
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

NCT01854658
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005), Placebo
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
113
States / cities
Birmingham, Alabama • Florence, Alabama • Jasper, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT03162055
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease COPD
Interventions
Glycopyrronium/Formoterol Fumarate, umeclidinium/vilanterol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 95 Years
Enrollment
1,119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Tempe, Arizona • Escondido, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

NCT01854645
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
2,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

NCT01970878
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
110
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Jun 7, 2026, 9:22 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

NCT06878261
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
68
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

NCT02497001
View directory record Official record
Conditions
COPD
Interventions
BGF MDI 320/14.4/9.6 μg, GFF MDI (PT003) 14.4/9.6 μg, BFF MDI (PT009) 320/9.6 μg, Symbicort® Turbuhaler® (TBH) Inhalation Powder
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
63
States / cities
Andalusia, Alabama • Jasper, Alabama • Peoria, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT05573464
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
BGF MDI HFO 320/14.4/9.6 μg, BGF MDI HFA 320/14.4/9.6 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Newport Beach, California • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Tezepelumab COPD Exacerbation Study

NCT04039113
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
27
States / cities
Dothan, Alabama • Huntington Beach, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD

NCT02268396
View directory record Official record
Conditions
COPD
Interventions
Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

NCT02465567
View directory record Official record
Conditions
COPD
Interventions
BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BGF MDI 160/14.4/9.6 μg, BFF MDI 320/9.6 μg
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
8,588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
318
States / cities
Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 249 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jun 7, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AZD6793, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
86
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 7, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

Peak Inspiratory Flow Rates in Patients With COPD

NCT04168775
View directory record Official record
Conditions
COPD
Interventions
Home PIFR monitoring with InCheck Dial
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Jun 7, 2026, 9:22 AM EDT